EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single‐plex testing: WJOG13620L

Takehiro Uemura iD, Hirotsugu Kenmotsu iD, Daisuke Hazama, Shunsuke Teraoka, Hiroshi Kobe, Koichi Azuma iD, Teppei Yamaguchi, Takeshi Masuda iD, Toshihide Yokoyama, Kohei Otsubo iD, Koji Haratani, Daisuke Hayakawa und 8 weitere

Cancer Medicine · 2023-12 · 12 (23) · 21097-21110

DOI: 10.1002/cam4.6668 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer Medicine, online erschienen am 10.11.2023. Verfasst von Takehiro Uemura und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guardant Health AMEA, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Actionable tumor genomic alterations, primarily EGFR mutations, occur in nearly 70% of Japanese advanced nonsquamous non‐small cell lung cancer (NSCLC) patients. Standard assessment of tumor tissue includes rapid testing for EGFR mutations, ALK fusions and ROS1 fusions. We conducted a prospective observational study (WJOG13620L) of follow‐on next‐generation sequencing of circulating tumor DNA (ctDNA) in patients without driver alterations after EGFR testing.

Methods

Patients with untreated advanced (Stage IIIB–IV or relapsed) nonsquamous NSCLC without EGFR mutations according to single‐plex testing of tumor tissue, were enrolled into this study. Patients with other known driver mutations or who underwent comprehensive genomic profiling were excluded. Plasma was analyzed by Guardant360, and the primary endpoint was the proportion of patients with pathogenic gene alterations in at least one of nine genes.

Results

Among the 72 patients enrolled, ALK and ROS1 fusions were tested in 86.1% and 65.2%, respectively. Alterations in pre‐defined genes were detected in 21 patients (29.2%; 95% confidence interval: 19.0–41.1, p < 0.001 [one‐sided null hypothesis proportion of 10%]), including RET fusion ( n = 1) and mutations in KRAS ( n = 11), EGFR ( n = 5), ERBB2 ( n = 3), and BRAF ( n = 1). Median time from sample submission to results was 8 days (range, 5–17 days).

Conclusion

Rapid follow‐on comprehensive testing of ctDNA should be considered prior to first‐line treatment for patients with advanced nonsquamous NSCLC when no alterations are detected after single‐plex tissue testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansProtein-Tyrosine KinasesProto-Oncogene ProteinsMutationGenomicsLiquid BiopsyErbB Receptors

Stichwörter der Autor:innen

circulating tumor DNAliquid biopsylung cancermolecularly targeted therapymultiplex gene analysis

Substanzen

Protein-Tyrosine KinasesProto-Oncogene ProteinsErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
  • Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
  • Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
  • Internal Medicine III, Wakayama Medical University, Wakayama, Wakayama, Japan.
  • Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.
  • Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan.

ORCID-Profile: Takehiro Uemura, Hirotsugu Kenmotsu, Koichi Azuma, Takeshi Masuda, Kohei Otsubo, Masahide Oki, Shinnosuke Takemoto, Akito Hata

Förderung

  • Guardant Health AMEA, Inc

Zitieren

APA

Uemura, T., Kenmotsu, H., Hazama, D., Teraoka, S., Kobe, H., Azuma, K., Yamaguchi, T., Masuda, T., Yokoyama, T., Otsubo, K., Haratani, K., Hayakawa, D., Oki, M., Takemoto, S., Ozaki, T., Akashi, Y., Hata, A., Hashimoto, H., Yamamoto, N., & Nakagawa, K. (2023). Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single‐plex testing: WJOG13620L. Cancer Medicine, 12(23), 21097-21110. https://doi.org/10.1002/cam4.6668

Vancouver

Uemura T, Kenmotsu H, Hazama D, Teraoka S, Kobe H, Azuma K, et al. Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single‐plex testing: WJOG13620L. Cancer Medicine. 2023;12(23):21097-21110. doi:10.1002/cam4.6668

BibTeX
@article{Uemura2023,
  author = {Uemura, Takehiro and Kenmotsu, Hirotsugu and Hazama, Daisuke and Teraoka, Shunsuke and Kobe, Hiroshi and Azuma, Koichi and Yamaguchi, Teppei and Masuda, Takeshi and Yokoyama, Toshihide and Otsubo, Kohei and Haratani, Koji and Hayakawa, Daisuke and Oki, Masahide and Takemoto, Shinnosuke and Ozaki, Tomohiro and Akashi, Yusaku and Hata, Akito and Hashimoto, Hiroya and Yamamoto, Nobuyuki and Nakagawa, Kazuhiko},
  title = {Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single‐plex testing: WJOG13620L},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {23},
  pages = {21097--21110},
  doi = {10.1002/cam4.6668}
}
Kostenlos starten →